<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01760265</url>
  </required_header>
  <id_info>
    <org_study_id>1</org_study_id>
    <nct_id>NCT01760265</nct_id>
  </id_info>
  <brief_title>DARK STUDY &quot;DysbetalipoproteinemiA and atheRoma Risk&quot;</brief_title>
  <acronym>DARK</acronym>
  <official_title>Dysbetalipoproteinemia and Atheroma Risk : Assessment of Cardiovascular Risk in Dysbetalipoproteinemic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dysbetalipoproteinemia (type III, Fredrickson's classification) is a rare metabolic disorder.
      It results from a defect in the clearance of VLDL and chylomicron remnants due to homozygous
      APOE2 variants or heterozygous APOE mutations, and there is an elevated plasma cholesterol
      and triglycerides.

      As a consequence of the derangements in lipoprotein metabolism, dysbetalipoproteinemia
      predispose to the premature development of atherosclerosis.

      However among this population there is heterogeneity in development of cardiovascular
      complications and the determinants remain unclear actually.

      The aim of the investigators study is to evaluate the intensity of clinical atherosclerosis,
      and identify its determinants.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Computed tomographic measurements for coronary-artery calcium</measure>
    <time_frame>Day one : the coronary calcium score is assessed on the date of measurement</time_frame>
    <description>Comparison with eventual previous examinations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of carotid intima-media by ultrasonography</measure>
    <time_frame>Day one : on the date of measurement</time_frame>
    <description>Comparison with eventual previous examinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of ankle brachial index</measure>
    <time_frame>Day one : on the date of measurement</time_frame>
    <description>Comparison with eventual previous examinations</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Dysbetalipoproteinemia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Lipid, apo E genotype when is necessary to complete the phenotype
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Dysbetalipoproteinemia patients with APOE2/E2 or heterozygous mutation (negative dominance)
        and hypercholesterolemia, ratio CT VLDL/Tg VLDL &gt;0.40
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - apo E gene sequencing in CBE (Centre de Biologie Est / Hospices Civils de Lyon / France)
        laboratory in Lyon until December 2012

        Exclusion Criteria:

          -  age &lt; 40 years

          -  refused participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe MOULIN, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe MOULIN, Pr</last_name>
    <phone>4 72 68 13 04</phone>
    <phone_ext>+33</phone_ext>
    <email>philippe.moulin@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Groupement Hospitalier Est</name>
      <address>
        <city>Bron</city>
        <zip>69100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe MOULIN</last_name>
      <phone>4 72 68 13 04</phone>
      <phone_ext>+33</phone_ext>
      <email>Philippe.moulin@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe MOULIN, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2013</study_first_submitted>
  <study_first_submitted_qc>January 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2013</study_first_posted>
  <last_update_submitted>January 25, 2013</last_update_submitted>
  <last_update_submitted_qc>January 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dysbetalipoproteinemia</keyword>
  <keyword>artery calcium score</keyword>
  <keyword>carotid intima media</keyword>
  <keyword>ankle brachial index</keyword>
  <keyword>dysbetalipoproteinemic patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type III</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

